Neoadjuvant Anti-PD-1 Strategy Prevails Over Adjuvant in Resectable Melanoma
(MedPage Today) -- PARIS -- The randomized trial data have spoken, and they favor neoadjuvant immunotherapy over adjuvant treatment for resectable melanoma.
Neoadjuvant pembrolizumab (Keytruda) followed by surgery and additional pembrolizumab...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news
More News: Cancer & Oncology | Hematology | Immunotherapy | Melanoma | Neoadjuvant Therapy | Skin Cancer